About Alzheon
Alzheon is a company based in Framingham (United States) founded in 2013.. Alzheon has raised $195.25 million across 12 funding rounds from investors including NIH, HHS and Ally Bridge Group. Alzheon offers products and services including valiltramiprosate and ALZ-801. Alzheon operates in a competitive market with competitors including T3D Therapeutics, Longeveron, Alchemab, Cerecin and Totus Medicines, among others.
- Headquarter Framingham, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Future X Beta S.R.O.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$195.25 M (USD)
in 12 rounds
-
Latest Funding Round
$100 M (USD), Series E
Jun 12, 2024
-
Investors
NIH
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alzheon
Alzheon offers a comprehensive portfolio of products and services, including valiltramiprosate and ALZ-801. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational oral drug targeting amyloid oligomers in Alzheimer's disease
Oral treatment for early Alzheimer's in APOE4 carriers
Unlock access to complete
Unlock access to complete
Funding Insights of Alzheon
Alzheon has successfully raised a total of $195.25M across 12 strategic funding rounds. The most recent funding activity was a Series E round of $100 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Series E — $100.0M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2024 | Amount | Series E - Alzheon | Valuation | Alerce Medical Technology Partners |
|
| Feb, 2024 | Amount | Series D - Alzheon | Valuation |
investors |
|
| Apr, 2022 | Amount | Series D - Alzheon | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Alzheon
Alzheon has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Ally Bridge Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and hedge fund investments in healthcare are managed.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alzheon
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Alzheon
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alzheon Comparisons
Competitors of Alzheon
Alzheon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as T3D Therapeutics, Longeveron, Alchemab, Cerecin and Totus Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| domain | founded_year | HQ Location |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| domain | founded_year | HQ Location |
Medical foods and drugs for Alzheimer's disease are developed.
|
|
| domain | founded_year | HQ Location |
Genome-scale drug discovery platform is provided for treating multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alzheon
Frequently Asked Questions about Alzheon
When was Alzheon founded?
Alzheon was founded in 2013.
Where is Alzheon located?
Alzheon is headquartered in Framingham, United States. It is registered at Framingham, Massachusetts, United States.
Is Alzheon a funded company?
Alzheon is a funded company, having raised a total of $195.25M across 12 funding rounds to date. The company's 1st funding round was a Series D of $50M, raised on Oct 23, 2013.
What does Alzheon do?
Alzheon was founded in 2013 and is headquartered in Framingham, United States. Focus is placed on the biotechnology sector, specifically the development of oral therapeutics for Alzheimers disease. The lead candidate, ALZ-801, a prodrug of tramiprosate, is advanced as an inhibitor targeting amyloid aggregation and neurotoxicity. Clinical operations are conducted to address key pathological hallmarks of the disease.
Who are the top competitors of Alzheon?
Alzheon's top competitors include Longeveron, Alchemab and Eikonizo.
What products or services does Alzheon offer?
Alzheon offers valiltramiprosate and ALZ-801.
Who are Alzheon's investors?
Alzheon has 4 investors. Key investors include NIH, HHS, Ally Bridge Group, and Alerce Medical Technology Partners.